Career development fellowship
List of mentors

Manuel Battegay

Institution: University Hospital Basel
City: Basel  Country: Switzerland

Areas of interest, expertise and active research programmes: HIV – Therapy and outcome, HIV – Ageing and multimorbidity, artificial Intelligence, HIV-Pharmacology

Sanjay Bhagani

Institution: Royal Free Hospital
City: London  Country: United Kingdom

Areas of interest, expertise and active research programmes: Managing complex OIs in the context of HIV immunosuppression and viral hepatitis/liver disease in HIV+ patients

Dominique Costagliola

Institution: INSERM and Sorbonne Université
City: Paris  Country: France

Areas of interest, expertise and active research programmes: Clinical research (epidemiology or clinical trials) with special interest in comorbidities

Antonella d’Arminio Monforte

Institution: San Paolo University Hospital
City: Milan  Country: Italy

Areas of interest, expertise and active research programmes: Observational studies, immunological markers associated to response to HIV therapy, acute HIV and immune markers, HCV coinfection
M. John Gill

Institution: S Alberta HIV Clinic
City: Calgary  Country: Canada
Areas of interest, expertise and active research programmes: HIV epidemiology, HIV outcomes, cost of care

Christine Katlama

Institution: Pitié-Salpêtrière University Hospital
City: Paris  Country: France
Areas of interest, expertise and active research programmes: Antiretroviral therapy, PrEP, comorbidities

Karine Lacombe

Institution: Saint-Antoine University Hospital
City: Paris  Country: France
Areas of interest, expertise and active research programmes: HIV-hepatitis co-infection, HIV-tuberculosis co-infection, comorbidities associated with HIV, STIs and PrEP

Jens D. Lundgren

Institution: Rigshospitalet, University of Copenhagen
City: Copenhagen  Country: Denmark
Areas of interest, expertise and active research programmes: Clinical and public health aspects of the HIV infection itself, and its infectious and noninfectious associated morbidities
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>City</th>
<th>Country</th>
<th>Areas of interest, expertise and active research programmes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esteban Martinez</td>
<td>Hospital Clínic of Barcelona</td>
<td>Barcelona</td>
<td>Spain</td>
<td>Antiretroviral therapy strategies, toxicity of antiretrovirals, and non-infectious complications and comorbidities in HIV-positive adults</td>
</tr>
<tr>
<td>Cristina Mussini</td>
<td>University of Modena and Reggio Emilia</td>
<td>Modena</td>
<td>Italy</td>
<td>Immunopathology of HIV, comorbidities, ageing and frailty, treatment strategies, impact of dolutegravir + lamivudine or biktarvi on CD4/CD8 ratio</td>
</tr>
<tr>
<td>Cristiana Oprea</td>
<td>Victor Babes Clinical Hospital</td>
<td>Bucharest</td>
<td>Romania</td>
<td>HIV and opportunistic infections (including TB), HIV and hepatitis co-infection, HIV and comorbidities/co-infections in key populations (injecting drug users), standards of care for HIV and co-infections; Active research programmes: HIV and HCV co-infection in key populations</td>
</tr>
<tr>
<td>Peter Reiss</td>
<td>Academic Medical Centre, University of Amsterdam</td>
<td>Amsterdam</td>
<td>Netherlands</td>
<td>Improving our understanding of what drives the increased risk of non-communicable comorbidity in people with treated HIV disease as they age, in comparison to uninfected individuals with similar demographics and lifestyle; reducing the number of new HIV infections in Amsterdam</td>
</tr>
<tr>
<td>Name</td>
<td>Institution</td>
<td>City</td>
<td>Country</td>
<td>Areas of interest, expertise and active research programmes</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------------------------------</td>
<td>------------</td>
<td>-----------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Jürgen Rockstroh</td>
<td>University Hospital Bonn</td>
<td>Bonn</td>
<td>Germany</td>
<td>HIV and liver disease, research involves studies on acute HCV in HIV, HCV-elimination, treatment of HBV in HIV, and NASH and NAFLD in HIV</td>
</tr>
<tr>
<td>Alison Rodger</td>
<td>University College London and Royal Free NHS Foundation Trust</td>
<td>London</td>
<td>United Kingdom</td>
<td>HIV prevention, PrEP, HIV testing including self-testing, mental health in PLWH and interventions to improve health and well-being in PLWH</td>
</tr>
<tr>
<td>Caroline Sabin</td>
<td>University College London</td>
<td>London</td>
<td>United Kingdom</td>
<td>Statistical/epidemiological and with cohorts in HIV and ageing; clinical/epidemiological research focussed around data analysis</td>
</tr>
<tr>
<td>Linos Vandekerckhove</td>
<td>Ghent University Hospital</td>
<td>Ghent</td>
<td>Belgium</td>
<td>HIV research</td>
</tr>
<tr>
<td>Jaime Vera</td>
<td>Brighton and Sussex Medical School</td>
<td>Brighton</td>
<td>United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
Areas of interest, expertise and active research programmes: Study of comorbidities affecting people with HIV including HIV associated cognitive impairment (HAND) and the development and evaluation of innovative models of care including interventional studies aimed at improving quality of life, and mental well-being of older people with HIV and those affected by HAND in both low- and high-income settings. We have an active research unit with a large portfolio of academic and industry study. The mentoring will include opportunities in global HIV health through our collaborations in Zambia and South Africa.

Annemarie Wensing

Institution: University Medical Center Utrecht

City: Utrecht    Country: Netherlands

Areas of interest, expertise and active research programmes: HIV reservoirs and transmission and mechanisms of HIV drug resistance